Cronos Group (CRON) Competitors $2.09 -0.02 (-0.95%) (As of 10/31/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CRON vs. APLS, APGE, PTCT, EWTX, XENE, ZLAB, MLTX, IOVA, RYTM, and KYMRShould you be buying Cronos Group stock or one of its competitors? The main competitors of Cronos Group include Apellis Pharmaceuticals (APLS), Apogee Therapeutics (APGE), PTC Therapeutics (PTCT), Edgewise Therapeutics (EWTX), Xenon Pharmaceuticals (XENE), Zai Lab (ZLAB), MoonLake Immunotherapeutics (MLTX), Iovance Biotherapeutics (IOVA), Rhythm Pharmaceuticals (RYTM), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry. Cronos Group vs. Apellis Pharmaceuticals Apogee Therapeutics PTC Therapeutics Edgewise Therapeutics Xenon Pharmaceuticals Zai Lab MoonLake Immunotherapeutics Iovance Biotherapeutics Rhythm Pharmaceuticals Kymera Therapeutics Apellis Pharmaceuticals (NASDAQ:APLS) and Cronos Group (NASDAQ:CRON) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, risk, media sentiment, valuation, dividends and profitability. Does the MarketBeat Community believe in APLS or CRON? Cronos Group received 129 more outperform votes than Apellis Pharmaceuticals when rated by MarketBeat users. However, 67.68% of users gave Apellis Pharmaceuticals an outperform vote while only 61.13% of users gave Cronos Group an outperform vote. CompanyUnderperformOutperformApellis PharmaceuticalsOutperform Votes33567.68% Underperform Votes16032.32% Cronos GroupOutperform Votes46461.13% Underperform Votes29538.87% Do analysts recommend APLS or CRON? Apellis Pharmaceuticals currently has a consensus target price of $65.41, suggesting a potential upside of 139.96%. Cronos Group has a consensus target price of $3.00, suggesting a potential upside of 43.54%. Given Apellis Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Apellis Pharmaceuticals is more favorable than Cronos Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apellis Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.78Cronos Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has more risk and volatility, APLS or CRON? Apellis Pharmaceuticals has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Cronos Group has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Does the media refer more to APLS or CRON? In the previous week, Apellis Pharmaceuticals had 19 more articles in the media than Cronos Group. MarketBeat recorded 20 mentions for Apellis Pharmaceuticals and 1 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.94 beat Apellis Pharmaceuticals' score of 0.30 indicating that Cronos Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apellis Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Cronos Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in APLS or CRON? 96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 6.8% of Apellis Pharmaceuticals shares are owned by insiders. Comparatively, 6.9% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is APLS or CRON more profitable? Apellis Pharmaceuticals has a net margin of -52.99% compared to Cronos Group's net margin of -56.43%. Cronos Group's return on equity of -2.06% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Apellis Pharmaceuticals-52.99% -138.32% -39.63% Cronos Group -56.43%-2.06%-1.99% Which has better earnings & valuation, APLS or CRON? Cronos Group has lower revenue, but higher earnings than Apellis Pharmaceuticals. Cronos Group is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApellis Pharmaceuticals$628.79M5.26-$528.63M-$3.46-7.88Cronos Group$101.78M7.85-$73.96M-$0.15-13.93 SummaryApellis Pharmaceuticals beats Cronos Group on 10 of the 19 factors compared between the two stocks. Ad Porter & CompanyI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Get Cronos Group News Delivered to You Automatically Sign up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRON vs. The Competition Export to ExcelMetricCronos GroupMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$799.00M$1.28B$5.37B$8.41BDividend YieldN/AN/A5.23%4.20%P/E Ratio-13.938.57131.9117.69Price / Sales7.857.551,441.8380.21Price / CashN/A15.2439.1233.56Price / Book0.731.834.744.57Net Income-$73.96M-$52.95M$115.66M$225.49M7 Day Performance-4.57%4.54%-0.88%-0.61%1 Month Performance-4.57%1.61%3.59%1.50%1 Year Performance15.47%6.89%38.93%32.93% Cronos Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRONCronos Group1.8452 of 5 stars$2.09-0.9%$3.00+43.5%+19.2%$799.00M$101.78M-13.93356APLSApellis Pharmaceuticals4.4012 of 5 stars$27.36+0.1%$65.41+139.1%-42.2%$3.32B$628.79M-9.99702Upcoming EarningsAnalyst RevisionAPGEApogee Therapeutics2.713 of 5 stars$56.30+2.5%$78.50+39.4%+229.3%$3.29BN/A-27.2091PTCTPTC Therapeutics2.7637 of 5 stars$42.43+4.8%$40.08-5.5%+117.0%$3.26B$937.82M-6.721,410Upcoming EarningsEWTXEdgewise Therapeutics1.9281 of 5 stars$34.40+1.1%$35.60+3.5%+387.8%$3.23BN/A-22.1960Short Interest ↓Positive NewsXENEXenon Pharmaceuticals3.429 of 5 stars$41.730.0%$57.45+37.7%+33.0%$3.15B$9.43M-15.23251Options VolumePositive NewsZLABZai Lab2.7852 of 5 stars$31.41-3.5%$52.50+67.1%+21.5%$3.13B$322.71M-10.262,175Gap DownMLTXMoonLake Immunotherapeutics1.927 of 5 stars$48.32+0.6%$80.45+66.5%-3.9%$3.09BN/A-53.102Positive NewsIOVAIovance Biotherapeutics3.7889 of 5 stars$10.82-1.9%$22.33+106.4%+198.4%$3.03B$32.77M-6.48500Upcoming EarningsRYTMRhythm Pharmaceuticals4.0396 of 5 stars$49.54+0.2%$60.33+21.8%+117.6%$3.02B$101.78M-11.36140Upcoming EarningsAnalyst ForecastKYMRKymera Therapeutics0.7816 of 5 stars$48.51-1.2%$49.00+1.0%+324.9%$2.98B$88.55M-20.05170News Coverage Related Companies and Tools Related Companies APLS Alternatives APGE Alternatives PTCT Alternatives EWTX Alternatives XENE Alternatives ZLAB Alternatives MLTX Alternatives IOVA Alternatives RYTM Alternatives KYMR Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRON) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cronos Group Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cronos Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
